Dipeptidyl peptidase IV inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Drug Discovery

Background:

• Dipeptidyl peptidase IV (DPP-IV) inhibitors have garnered significant interest for their therapeutic potential in managing diabetes.
• The review specifically examines reversible DPP-IV inhibitors, primarily targeting Type II diabetes treatment.

Purpose of the Study:

• To review patent literature on dipeptidyl peptidase IV (DPP-IV) inhibitors from January 2001 to May 2002.
• To focus on reversible DPP-IV inhibitors and their application in Type II diabetes.
• To identify new chemical entities and emerging indications for DPP-IV inhibitors.

Main Methods:

• Comprehensive review of patent literature published between January 2001 and May 2002.
• Analysis of newly reported chemical entities, focusing on dipeptide-like and non-peptide inhibitors.
• Investigation of new indications identified through the use of existing DPP-IV inhibitors as research tools.

Main Results:

• The majority of new chemical entities reported are dipeptide-like inhibitors, mimicking preferred substrates and exhibiting nanomolar activity.
• Fewer non-peptide inhibitors were reported, indicating challenges in discovering novel inhibitor classes.
• New therapeutic indications for DPP-IV inhibitors were identified using established inhibitors as research tools.

Conclusions:

• Patent literature from 2001-2002 highlights significant advancements in dipeptidyl peptidase IV (DPP-IV) inhibitor development for Type II diabetes.
• Dipeptide-like reversible inhibitors represent a promising class, with some achieving high potency.
• Further research into non-peptide inhibitors and exploring new indications is warranted.